HC Wainwright & Co. Reiterates Buy on LifeMD, Maintains $9 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates LifeMD (NASDAQ:LFMD) with a Buy and maintains $9 price target.
Stocks · News reference
LifeMD Q2 EPS $(0.16) Misses $(0.15) Estimate, Sales $47.300M Miss $49.152M Estimate
LifeMD (NASDAQ:LFMD) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.15) by 6.67 percent. This is a 166.67 percent decrease over losses of $(0.06) per share from the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
FDA Says It Has Received 990 Adverse Event Reports Tied To Compounded Semaglutide And More Than 730 Tied To Compounded Tirzepatide; Establishes Import Alert For Compounded GLP-1 Active Pharmaceutical Ingredients
HC Wainwright & Co. Maintains Buy on LifeMD, Lowers Price Target to $9
HC Wainwright & Co. analyst Yi Chen maintains LifeMD (NASDAQ:LFMD) with a Buy and lowers the price target from $10 to $9.
B. Riley Securities Maintains Buy on LifeMD, Lowers Price Target to $8
B. Riley Securities analyst William Woods maintains LifeMD (NASDAQ:LFMD) with a Buy and lowers the price target from $10 to $8.